Navigating Market Access Hurdles

An exploration into how flawed incentives and contractual loopholes between manufacturers and pharmacy benefit managers played their part.

Alice Valder Curran outlines the steps manufacturers should take to better prepare for upcoming executive actions on drug pricing and market access.

The acquisition of Cryoport’s specialty courier business is now finalized, with a value of approximately $200 million.

Claire Riches highlights inefficiencies in the current drug approval process, while outlining the role of payers and insurers in shifting toward data-driven approval framework.

A cross-sectional study explores how full-benefit dual-eligible beneficiaries differ across MA plans with differing levels of Medicaid coordination and integration.

Marketed as BNT327, the PD-L1xVEGF-A bispecific antibody has the potential to become what the involved parties believe is a ‘foundational immuno-oncology backbone.’